A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans

Diabetes Care. 2003 Aug;26(8):2477-8. doi: 10.2337/diacare.26.8.2477.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin
  • Aged
  • Arteriosclerosis Obliterans / blood
  • Arteriosclerosis Obliterans / drug therapy*
  • Arteriosclerosis Obliterans / etiology
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications*
  • Female
  • Humans
  • Intercellular Signaling Peptides and Proteins*
  • Male
  • Middle Aged
  • Proteins / metabolism*
  • Serotonin Antagonists / therapeutic use*
  • Succinates / therapeutic use*

Substances

  • Adiponectin
  • Intercellular Signaling Peptides and Proteins
  • Proteins
  • Serotonin Antagonists
  • Succinates
  • sarpogrelate